Rabeprazole sodium: Clinical Trials

8 completed. 8 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	8	Completed 8

Follow Rabeprazole sodium: new trials by email Literature Review of Rabeprazole sodium trials Research Report on Rabeprazole sodium

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438) Vonoprazan, Esomeprazole, Rabeprazole sodium - Healthy Volunteers	Phase 3	Completed	Takeda	20	2014-01-01	2016-10-17
Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD) rabeprazole sodium, Placebo - Symptomatic Gastroesophageal Reflux Disease (sGERD)	Phase 3	Completed	Eisai Inc.	305	2009-01-01	2016-02-02
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD) Rabeprazole sodium, Esomeprazole - Gastroesophageal Reflux Disease (GERD)	Phase 3	Completed	Eisai Inc.	1061	2008-02-01	2015-12-21
Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD) Rabeprazole sodium, Esomeprazole - Gastroesophageal Reflux Disease (GERD)	Phase 3	Completed	Eisai Inc.	1069	2008-02-01	2015-12-21
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD) Rabeprazole sodium, Esomeprazole - Gastroesophageal Reflux Disease (GERD)	Phase 3	Completed	Eisai Inc.	1397	2008-02-01	2016-05-04
E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers rabeprazole sodium, Placebo - Heartburn	Phase 3	Completed	Eisai Inc.	629	2005-10-01	2010-04-06
E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers rabeprazole sodium, placebo - Heartburn	Phase 3	Completed	Eisai Inc.	619	2005-10-01	2009-11-11
A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease RABEPRAZOLE SODIUM - Non-erosive Gastroesophageal Reflux Disease	Phase 3	Completed	Eisai Inc.	26	2005-05-01	2011-10-05

Conditions studied

Gastroesophageal Reflux (4)  ·  Heartburn (2)

Sponsors

Eisai Inc. (7)  ·  Takeda (1)

Countries

United States (6)  ·  Argentina (2)  ·  Australia (2)  ·  Bulgaria (2)  ·  Canada (2)  ·  Chile (2)  ·  Croatia (2)  ·  Estonia (2)  ·  France (2)  ·  Germany (2)  ·  Hungary (2)  ·  India (2)  ·  Japan (2)  ·  Latvia (2)  ·  Lithuania (1)

Top investigators

Yufang Lu (3)  ·  Yufang Lu, MD, PhD (2)  ·  Guillermo Rossiter, MD (1)  ·  Nobuyuki Sugisaki (1)

Results publications

PMID 21114792